Emeryville, California-based Metagenomi, Inc., a precision genetic medicines company developing curative therapeutics using its proprietary, metagenomics-derived genome editing toolbox, has priced initial public offering of 6.25 million shares of common stock at $15.00 per share.
Metagenomi shares will begin trading on the Nasdaq today, under the symbol MGX.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com